Developer of stem cell treatment solutions
Location: China
Employees: 11-50
Investors 2
| Date | Name | Website |
| - | Qiming Ven... | qimingvent... |
| 21.10.2021 | Qiming Ven... | qimingvc.c... |
Mentions in press and media 7
| Date | Title | Description |
| 14.04.2026 | Advances in Parkinson's Disease Cell Therapy: XellSmart Launches a Multicenter Phase II Clinical Trial Following Encouraging Phase I Results | SUZHOU, China, April 14, 2026 /PRNewswire/ -- In April 2026, XellSmart officially launches its multicenter Phase II registrational clinical trial of the "Clinical-Grade, Allogeneic, Off-the-Shelf, iPSC-Derived, Dopaminergic Neural Prog... |
| 02.03.2026 | XellSmart Receives Fourth Consecutive US FDA & China NMPA IND Clearance for MSA-P iPSC-derived Cell Therapy | SUZHOU, China, March 2, 2026 /PRNewswire/ -- In February 2026, XellSmart Pharmaceutical Co., Ltd. (XellSmart) announced that it had secured its fourth US FDA and China NMPA clearance for Phase I/II registrational clinical trial entry with i... |
| 28.07.2025 | XellSmart Completed World's First Patient Dosing in its Registrational Clinical trial for iPSC-derived Subtype-specific Neural Cell Therapy for Spinal Cord Injury | SUZHOU, China, July 28, 2025 /PRNewswire/ -- XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd. achieved a significant milestone in its "world's first" China NMPA & US FDA-approved registrational clinical trial. This Phas... |
| 03.07.2025 | Li Li of Next Capital Named in Caijing Magazine’s “Top 50 Global Chinese Venture Capitalists” | NEW YORK, USA – Media OutReach Newswire – 3 July 2025 – Recently, Li Li, Founding Partner of Next Capital, was honored as one of Caijing Magazine’s “Top 50 Global Chinese Venture Capitalists”. Awarded by Caijing, an authoritative media plat... |
| 26.05.2025 | World's First -- XellSmart's Allogeneic iPSC-derived Regenerative Cell Therapy for Spinal Cord Injury Officially Approved by the U.S. FDA for a Registrational Phase I Clinical Trial | SUZHOU, China, May 26, 2025 /PRNewswire/ -- In May 2025, XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd. officially announced that XellSmart-developed off-the-shelf allogeneic iPSC-derived subtype-specific neural regenerative cell t... |
| 15.04.2025 | XellSmart's Allogeneic iPSC-derived Cell Therapies for Parkinson's Disease and ALS Officially Approved by the U.S. FDA for Phase I Clinical Trials | SUZHOU, China, April 15, 2025 /PRNewswire/ -- In January 2025 (U.S. time), the U.S. Food and Drug Administration (FDA) officially approved the Investigational New Drug (IND) application submitted by XellSmart Biopharmaceutical (Suzhou) Co.,... |
| - | XellSmart | “Shize Biopharmaceutical (Suzhou) Co., Ltd.” |